Role of DDB2 in chemotherapeutic agents-induced apoptosis and platinum resistance

DDB2 在化疗药物诱导的细胞凋亡和铂类耐药中的作用

基本信息

  • 批准号:
    8711333
  • 负责人:
  • 金额:
    $ 24.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-01 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cisplatin is one of the most potent anti-tumor agents, which displays clinical activity against a wide variety of solid tumors. The anti-neoplastic activity of cisplatin results from cisplatin- induced DNA damage, which further triggers cellular apoptosis. However, the effective use of cisplatin is limited by the development of cisplatin resistance in cancer cells. Damaged DNA binding protein (DDB2) has been reported to be able to bind UV- or cisplatin-induced DNA damage, and believed to have a correlation with the apoptotic event, especially the apoptosis induced by DNA damaging agents. However, the relationship between DDB2 and cisplatin- induced apoptosis needs to be validated and the mechanism needs to be explored. The specific hypothesis addressed in this proposal is that DDB2 mediates cisplatin-induced apoptosis through binding DNA damage to relay the apoptotic signals, and regulating pro- and anti-apoptotic proteins; as a result, DDB2 deficiency confers cancer cells resistance to cisplatin. The proposed work will utilize relevant biochemical, biophysical, immunological, cellular and molecular technologies mostly established and ongoing in the PI's laboratory to address the following specific aims: (1) To validate the role of DDB2 in cisplatin-induced apoptosis and the relationship between DDB2 and Bcl-2 in varying cancer cell lines and human tumor tissues; (2) To define the role of DDB2 recognition of cisplatin-induced DNA damage in triggering apoptosis; (3) To delineate the mechanism through which DDB2 down-regulates Bcl-2 level; (4) To reveal the relationship between DDB2 and p53 in the cisplatin-induced apoptosis; (5) To test the role of DDB2 in cisplatin sensitivity and cisplatin- induced apoptosis in vivo. The experimental focus of this proposal is on the relationship between DDB2 and apoptosis. Thus, the above-mentioned specific aims are designed to provide a comprehensive assessment of the regulatory function of DDB2 on cisplatin-induced apoptosis and the development of cisplatin resistance.
描述(由申请人提供):顺铂是最有效的抗肿瘤药物之一,它显示出针对各种实体瘤的临床活性。顺铂的抗塑性活性是由顺铂诱导的DNA损伤引起的,这进一步触发了细胞凋亡。然而,有效使用顺铂受到癌细胞中顺铂耐药性的发展的限制。据报道,受损的DNA结合蛋白(DDB2)能够结合UV-或顺铂诱导的DNA损伤,并被认为与凋亡事件有相关性,尤其是由DNA损害剂引起的凋亡。但是,需要验证DDB2与顺铂诱导的细胞凋亡之间的关系,需要探索该机制。该提案中解决的具体假设是,DDB2通过结合DNA损伤介导顺铂诱导的凋亡,从而传递凋亡信号,并调节促促凋亡蛋白。结果,DDB2缺乏赋予癌细胞对顺铂的抗性。 The proposed work will utilize relevant biochemical, biophysical, immunological, cellular and molecular technologies mostly established and ongoing in the PI's laboratory to address the following specific aims: (1) To validate the role of DDB2 in cisplatin-induced apoptosis and the relationship between DDB2 and Bcl-2 in varying cancer cell lines and human tumor tissues; (2)定义DDB2识别顺铂诱导的DNA损伤在触发凋亡中的作用; (3)描述DDB2下调Bcl-2水平的机制; (4)揭示了顺铂诱导的凋亡中DDB2和P53之间的关系; (5)测试DDB2在顺铂灵敏度和顺铂诱导的体内凋亡中的作用。该提议的实验重点是DDB2和凋亡之间的关系。因此,上述特定目的旨在对DDB2在顺铂诱导的细胞凋亡和顺铂耐药性的发展进行全面评估。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
DDB2 increases radioresistance of NSCLC cells by enhancing DNA damage responses.
miR-93 promotes TGF-β-induced epithelial-to-mesenchymal transition through downregulation of NEDD4L in lung cancer cells.
XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression.
  • DOI:
    10.18632/oncotarget.3542
  • 发表时间:
    2015-04-30
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Cui T;Srivastava AK;Han C;Yang L;Zhao R;Zou N;Qu M;Duan W;Zhang X;Wang QE
  • 通讯作者:
    Wang QE
DNA damage responses in cancer stem cells: Implications for cancer therapeutic strategies.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Qien Wang其他文献

Qien Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Qien Wang', 18)}}的其他基金

Role of ALDH in PARP inhibitor resistance in HR-deficient ovarian cancer
ALDH 在 HR 缺陷卵巢癌 PARP 抑制剂耐药中的作用
  • 批准号:
    10394792
  • 财政年份:
    2021
  • 资助金额:
    $ 24.56万
  • 项目类别:
Role of ALDH in PARP inhibitor resistance in HR-deficient ovarian cancer
ALDH 在 HR 缺陷卵巢癌 PARP 抑制剂耐药中的作用
  • 批准号:
    10606619
  • 财政年份:
    2021
  • 资助金额:
    $ 24.56万
  • 项目类别:
Averting recurrent and resistant ovarian tumors
避免复发性和耐药性卵巢肿瘤
  • 批准号:
    10058817
  • 财政年份:
    2016
  • 资助金额:
    $ 24.56万
  • 项目类别:
Role of DDB2 in chemotherapeutic agents-induced apoptosis and platinum resistance
DDB2 在化疗药物诱导的细胞凋亡和铂类耐药中的作用
  • 批准号:
    8323286
  • 财政年份:
    2011
  • 资助金额:
    $ 24.56万
  • 项目类别:
Role of DDB2 in chemotherapeutic agents-induced apoptosis and platinum resistance
DDB2 在化疗药物诱导的细胞凋亡和铂类耐药中的作用
  • 批准号:
    8516879
  • 财政年份:
    2011
  • 资助金额:
    $ 24.56万
  • 项目类别:
Role of DDB2 in chemotherapeutic agents-induced apoptosis and platinum resistance
DDB2 在化疗药物诱导的细胞凋亡和铂类耐药中的作用
  • 批准号:
    8050717
  • 财政年份:
    2011
  • 资助金额:
    $ 24.56万
  • 项目类别:

相似国自然基金

基于巨噬细胞表型转变探讨BTSA1诱导衰老肌成纤维细胞凋亡及促肺纤维化消退的机制
  • 批准号:
    82370077
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
STAB1调控Fas/FasL介导牦牛胎盘滋养层细胞凋亡及胎盘炎症性流产的作用与机制研究
  • 批准号:
    32360836
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
ATAD3A琥珀酰化调控mtDNA损伤-泛凋亡反应轴在心梗后心衰中的作用研究
  • 批准号:
    82300434
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
胸腺肽α-1介导凋亡小体RNA改善DC功能增强TNBC化疗后抗肿瘤免疫应答的机制研究
  • 批准号:
    82303959
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
LSD1通过使组蛋白H3K4位点去甲基化促进自噬参与肾小管上皮细胞凋亡和肾脏纤维化的机制研究
  • 批准号:
    82300769
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Ceramides as Novel Mediators of Tubular Metabolic Dysfunction Driving Kidney Injury
神经酰胺作为肾小管代谢功能障碍驱动肾损伤的新型调节剂
  • 批准号:
    10677394
  • 财政年份:
    2023
  • 资助金额:
    $ 24.56万
  • 项目类别:
Mining host-microbe interactions in the neonatal pancreas to combat diabetes
挖掘新生儿胰腺中宿主-微生物的相互作用来对抗糖尿病
  • 批准号:
    10664448
  • 财政年份:
    2023
  • 资助金额:
    $ 24.56万
  • 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
  • 批准号:
    10585802
  • 财政年份:
    2023
  • 资助金额:
    $ 24.56万
  • 项目类别:
Detection of Emergent Mechanical Properties of Biologically Complex Cellular States
生物复杂细胞状态的紧急机械特性的检测
  • 批准号:
    10832871
  • 财政年份:
    2023
  • 资助金额:
    $ 24.56万
  • 项目类别:
Molecular Origins and Evolution to Chemoresistance in Germ Cell Tumors
生殖细胞肿瘤化疗耐药的分子起源和进化
  • 批准号:
    10773483
  • 财政年份:
    2023
  • 资助金额:
    $ 24.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了